Abstract
Background
Clinical deterioration of relapsing–remitting MS (RR-MS) patients reflects not only the number and severity of overt inflammatory and demyelinating episodes, but also subtle central damage caused by persistent exposure to inflammatory molecules.
Objective
To explore the correlation between levels of CSF inflammatory molecules at the time of diagnosis and both demographic and clinical characteristics of a large sample of RR-MS patients, as well as the predictive value of cytokine levels on their prospective disease course.
Methods
In 205 patients diagnosed with RR-MS, we measured at the time of diagnosis the CSF levels of inflammatory molecules. Clinical and MRI evaluation was collected at the time of CSF withdrawal and during a median follow-up of 3 years.
Results
The time interval between the first anamnestic episode of focal neurological dysfunction and RR-MS diagnosis was the main factor associated with high CSF levels of IL-6 and IL-8. Furthermore, elevated CSF levels of these cytokines correlated with enhanced risk of clinical and radiological disease reactivation, switch to second-line treatments, and with disability progression in the follow-up.
Conclusions
Delayed diagnosis and treatment initiation are associated with higher CSF levels of IL-6 and IL-8 in RR-MS, leading to worsening disease course and poor response to treatments.
Similar content being viewed by others
References
Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N (2008) Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 131:288–303. https://doi.org/10.1093/brain/awm291
Linker RA, Sendtner M, Gold R (2005) Mechanisms of axonal degeneration in EAE lessons from CNTF and MHC I knockout mice. J Neurol Sci 233:167–172. https://doi.org/10.1016/j.jns.2005.03.021
Dihb-Jalbut S, Arnold DL, Cleveland DW et al (2006) Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 176:198–215
Maimone D, Gregory S, Arnason BG, Reder AT (1991) Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 32:67–74
Matejčíková Z, Mareš J, Sládková V et al (2017) Cerebrospinal fluid and serum levels of interleukin-8 in patients with multiple sclerosis and its correlation with Q-albumin. Mult Scler Relat Disord 14:12–15. https://doi.org/10.1016/j.msard.2017.03.007
Kothur K, Wienholt L, Brilot F, Dale RC (2016) CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review. Cytokine 7:227–237. https://doi.org/10.1016/j.cyto.2015.10.001
Magliozzi R, Howell O, Vora A et al (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089–1104. https://doi.org/10.1093/brain/awm038
Rossi S, Motta C, Studer V et al (2014) Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler 20:304–312. https://doi.org/10.1177/1352458513498128
Rossi S, Studer V, Motta C et al (2014) Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis. J Neuroinflammation 11:32. https://doi.org/10.1186/1742-2094-11-32
Rossi S, Motta C, Studer V et al (2015) Subclinical central inflammation is risk for RIS and CIS conversion to MS. Mult Scler 21:1443–1452. https://doi.org/10.1177/1352458514564482
Centonze D, Muzio L, Rossi S et al (2009) Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 29:3442–3452. https://doi.org/10.1523/JNEUROSCI.5804-08.2009
Mandolesi G, Musella A, Gentile A et al (2013) Interleukin–1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis. J Neurosci 33:12105–12121. https://doi.org/10.1523/JNEUROSCI.5369-12.2013
Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 69:292–302. https://doi.org/10.1002/ana.22366
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
Gutcher I, Becher B (2007) APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Investig 117:1119–1127. https://doi.org/10.1172/JCI31720
Bielekova B, Komori M, Xu Q et al (2012) Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One 7:e48370. https://doi.org/10.1371/journal.pone.0048370
Ishizu T, Osoegawa M, Mei FJ et al (2005) Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128:988–1002. https://doi.org/10.1093/brain/awh453
Maimone D, Guazzi GC, Annunziata P (1997) IL-6 detection in multiple sclerosis brain. J Neurol Sci 146:59–65
Matsushita T, Tateishi T, Isobe N et al (2013) Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 8:e61835. https://doi.org/10.1371/journal.pone.0061835
Kimura A, Takemura M, Saito K et al (2017) Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder. J Neuroimmunol 305:175–181. https://doi.org/10.1016/j.jneuroim.2017.01.006
Stelmasiak Z, Kozioł-Montewka M, Dobosz B et al (2000) Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients. Med Sci Monit 6:1104–1108
Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904. https://doi.org/10.1056/NEJM200009283431301
Comi G, Filippi M, Barkhof F et al (2001) Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582
Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249. https://doi.org/10.1212/01.wnl.0000237641.33768.8d
Kappos L, Freedman MS, Polman CH et al (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8:987–997. https://doi.org/10.1016/S1474-4422(09)70237-6
Kappos L, Edan G, Freedman MS et al (2016) The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87:978–987. https://doi.org/10.1212/WNL.0000000000003078
Rossi S, Furlan R, De Chiara V et al (2012) Interleukin–1β causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol 71:76–83. https://doi.org/10.1002/ana.22512
Stampanoni Bassi M, Mori F, Buttari F et al (2017) Neurophysiology of synaptic functioning in multiple sclerosis. Clin Neurophysiol 128:1148–1157. https://doi.org/10.1016/j.clinph.2017.04.006
Bermel RA, Bakshi R (2006) The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5:158–170. https://doi.org/10.1016/S1474-4422(06)70349-0
Fox NC, Jenkins R, Leary SM et al (2000) Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 54:807–812
Simon HJ, Jacobs LD, Campion MK et al (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 53:139–148
De Stefano N, Airas L, Grigoriadis N et al (2014) Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 28:147–156. https://doi.org/10.1007/s40263-014-0140-z
Skrzipek S, Vogelgesang A, Bröker BM, Dressel A (2012) Differential effects of interferon-β1b on cytokine patterns of CD4 + and CD8 + T cells derived from RRMS and PPMS patients. Mult Scler 18:674–678. https://doi.org/10.1177/1352458511427317
Gentile A, Musella A, Bullitta S et al (2016) Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation 13:207. https://doi.org/10.1186/s12974-016-0686-4
Gentile A, Musella A, De Vito F et al (2018) Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake. J Neuroinflammation 15:5. https://doi.org/10.1186/s12974-017-1048-6
Thompson AJ, Banwell BL, Barkhof F et al (2017) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://doi.org/10.1016/S1474-4422(17)30470-2
Acknowledgements
The present study was supported by the Italian Ministry of Health (Ricerca Corrente), and by the 5 × 1000 grant to IRCCS Neuromed.
Author information
Authors and Affiliations
Contributions
MSB: conception and design of the study, drafting a significant portion of the manuscript or figures. EI: conception and design of the study, drafting a significant portion of the manuscript or figures. DL: acquisition and analysis of data. FM: acquisition and analysis of data. LG: acquisition and analysis of data. IS: statistical analysis of data. AM: acquisition and analysis of data. GM: acquisition and analysis of data. FV: acquisition and analysis of data. RF: analysis of data. AF: analysis of data. GAM: acquisition and analysis of data. DC: conception and design of the study, drafting a significant portion of the manuscript or figures. FB: conception and design of the study, drafting a significant portion of the manuscript or figures.
Corresponding author
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Rights and permissions
About this article
Cite this article
Stampanoni Bassi, M., Iezzi, E., Landi, D. et al. Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. J Neurol 265, 2540–2547 (2018). https://doi.org/10.1007/s00415-018-8994-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-018-8994-5